PI
CLBT icon

PEAK6 Investments’s Cellebrite CLBT Stock Holding History

PEAK6 Investments’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-122,000
Closed -$978K – 5285
2021
Q4 		$978K Sell
122,000
-132,300
-52% -$1.25M ﹤0.01% 2588
2021
Q3 		$2.35M Buy
+254,300
New +$2.66M 0.01% 1800

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.02B AUM 9.21% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

PEAK6 Investments's CLBT Position: Q3 2024 in Review

PEAK6 Investments sold out of Cellebrite (CLBT) in Q3 2024, closing a stake of 20,720 shares — an estimated $248K sold.

PEAK6 Investments first reported a position in CLBT in Q3 2021 and held it in 4 quarters. The position peaked at $319K in Q1 2024. 164 funds tracked by Wall St. Rank hold CLBT as of Q3 2024.

  • PEAK6 Investments reported no remaining Cellebrite position as of Q3 2024 after selling out during the quarter.
  • PEAK6 Investments sold 20,720 Cellebrite shares in Q3 2024, an estimated $248K.
  • PEAK6 Investments first reported a position in Cellebrite in Q3 2021 and held it in 4 quarters.
  • PEAK6 Investments's Cellebrite position peaked at $319K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Cellebrite as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.